Skip to main content
. Author manuscript; available in PMC: 2010 Jul 1.
Published in final edited form as: Eur J Cancer. 2009 Apr 5;45(10):1855–1864. doi: 10.1016/j.ejca.2009.03.003

Figure 4. In vivo efficacy of the combination of PM02734 and erlotinib in an orthotopic NSCLC xenograft model.

Figure 4

Nude mice were implanted intravenously with 4.2 × 106 (A) or 8.4 ×106 (B) human A549 NSCLC cells. Nine days later, the mice were randomly divided into 4 groups with 5 (in A) or 7 (in B) mice per group. One group of mice received the combination treatment; the other groups were treated with PM02734 alone or erlotinib alone or without treatment. The survival or % Increased Life Span was determined. Log-rank test was used for the statistical analysis: p = 0.0003 (A) and p = 0.002 (B) for the combination group vs. the other groups.